A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 404173 Administered Once Weekly to Obese Patients With Type 2 Diabetes Mellitus Being Treated With Metformin or Metformin Plus Sulfonylurea

Trial Profile

A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 404173 Administered Once Weekly to Obese Patients With Type 2 Diabetes Mellitus Being Treated With Metformin or Metformin Plus Sulfonylurea

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs IONIS-PTP1BRx (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ionis Pharmaceuticals; Isis Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 03 Feb 2015 Primary endpoint 'Change in plasma HbA1c levels at Week 27 compared to Baseline as a measure of efficacy' has been met according to an Isis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top